Cite
HARVARD Citation
Bossuyt, P. et al. (n.d.). S772 Risankizumab Therapy Induces Improvements in Endoscopic Endpoints in Patients With Moderate-To-Severe Crohn's Disease: Results From the Phase 3 ADVANCE and MOTIVATE Studies. American journal of gastroenterology. pp. S357-S358. [Online].